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CHAPTER I
INTRODUCTION

Osteogenesis imperfecta (OI) is a heterogeneous genetic
disorder

that

affects

bone

and

other

connective

tissue

(Sillence et al., 1979a; Sillence et al., 1979b; Prockop and
Kivirikko,

1984a) .

It

is

characterized by fragility

of

bones, blue sclerae, thin skin, joint hypermobility, hearing
impairment

and

dentinogenesis

imperfecta

Byers 1989; Kuivaniemi et al., 1991).
tissues are rich in type I collagen
1988; Kuhn 1987).
synthesis

of

(Sillence

1988;

All of the affected
(Byers 1990; Sillence

Molecular defects in the structure and

Type

I

collagen

have

individuals with the OI phenotype

been

found

in

(Prockop et al.,

many
1989;

Prockop et al., 1994).
Severity of

the

OI

symptoms

varies

greatly between

individuals and very rarely have two cases been found with
exactly the same molecular defect (Pope et al., 1985; Rose et
al.,

1994).

There

asymptomatic
defect

as

are

individuals

those

family

reports
carry

of

the

members

many

same

with

cases

Type
the

OI

I

where

collagen
phenotype

(Superti-Furga et al., 1989; Cohn and Byers, 1991; Sykes et
al., 1990).

There have even been cases of the progressively-

deforming, moderately severe form of the disease (Type III)
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that show no apparent Type I collagen defects (Byers et al.,
1988b; Wenstrup et al., 1990).

Thus additional genes must

contribute to the OI phenotype other than the Type I collagen
genes.
Previous

studies

have

shown

the

existence

of

two

undescribed collagen-like loci that are different from other
already-characterized collagen genes (Cammarata et al., 1991;
Doering et al., 1993; Cammarata, 1994).

Site 1 is detected

as a 7.4kb Hind III restriction fragment which contains a
3. Okb

Pst

I

fragment

in normal

individuals.

Site

2

is

detected as a 4.6kb Hind III fragment that overlaps with a
5.2kb Pst I fragment in normal individuals.

This site has

recently been cloned and localized to chromosome 17 (Doering
et al.,

1993; Cammarata, 1994). Deletions at the two sites

occur more

frequently

in

OI Type

III patients

than the

normal population (Cammarata et al.,

1991; Doering et al.,

1987).

the

At

both of

the

new

sites

deletions

are

of

heterogeneous size and occur spontaneously (Doering et al.,
1987).

This data for OI patients, when compared to that for

normal individuals demonstrates that the frequent occurrence
of deletions at these loci is associated with Type III OI.
The new loci may code for a component(s) of connective tissue
that can contribute to the OI phenotype if defective, or may
interact with Type
phenotype.

I

collagen defects

to produce

the

OI

3

Tandemly-repeated

sequences

have

been

shown

to

be

responsible for disorders such as fragile X syndrome and
myotonic dystrophy, where length polymorphisms occur as a
result of variable numbers of copies of repeats
al.,

1992).

Also,

a

locus

containing

(Caskey et

uncharacterized

collagen-like sequences has been shown to have substantial
length polymorphism arising from variable numbers of tandem
repeats (Brookes et al., 1989).

These studies suggest that

tandemly repeated sequences are inherently unstable and prone
to further deletion.

Variability in the number of copies of

the repetitive sequence are what cause such heterogeneity
among individuals.
The purpose of this study was to localize and determine
the molecular organization of the deletion site at Site 2.
Specifically
repetitive

I

wished

sequences

are

to

determine

responsible

whether
for

this

tandemly
deletion.

Restriction enzymes with sites in the locus were used to
digest patient and normal DNAs
deletion site.

in order to localize the

Comparison of the fragment sizes obtained

from the normal to those from the patient DNA delineated this
localization.
the

clone

The regions surrounding the deletion site in
were

characteristics.

then

sequenced

to

determine

their

Sequences adjacent to the deletion site

that were non-repetitive and non-complementary were used to
construct DNA primers for PCR reactions.

The polymerase

chain reaction was utilized to amplify the patient DNA to
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allow sequencing of these regions.

The products of the PCR

reaction were electrophoresed on agarose gels,

and since

heterozygotes were used, two different-sized allele fragments
were separated from each other and purified by band-stab PCR
directly from the gel. The PCR-amplified Site 2 fragment was
then directly sequenced using Cycle-Sequencing methods.

The

characterization of the deletion in the patient was perf armed
by comparing the sequence of this allele to that of

the

normal

and

allele.

This

identified

deletion

endpoints,

indicates that tandemly repetitive sequences are involved in
the mechanism causing the deletions.

CHAPTER II
REVIEW OF RELATED LITERATURE

OI and Type I Collagen
Osteogenesis imperfecta (OI) is a heritable
connective-tissue disorder in which bone fragility is the
main clinical manifestation (Cole et al., 1989; Byers 1989;
Bateman et al., 1991).

It is one of the most common

connective tissue disorders and occurs with a frequency of
approximately 1 in 5,000 to 10,000 individuals (Byers and
Steiner, 1992).

The severity of the symptoms vary and

patients may also exhibit blue sclerae, hearing loss, thin
skin, joint hypermobility and dentinogenesis imperfecta
(Sillence, 1988; Byers, 1989).

Since all the tissues

affected by OI are rich in Type I collagen (Kuhn, 1987;
Sillence, 1988; Byers, 1989), most studies of the disease
have focused on the structure of this protein.

Many cases

of OI have been shown to involve alterations in the
structure and/or synthesis of Type I collagen, but only
rarely are two cases found with exactly the same defect
(Rose, 1994) .

The phenotype is caused by mutations in

either of the genes encoding the al or a2 chains of Type I
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collagen, COLlAl or COL1A2 (Rose et al., 1994; Forlino et
al., 1994).
Type I collagen is the major protein of mature bone,
skin, tendons and ligaments (Kuhn, 1987; Sillence, 1988)
Collagens are extracellular proteins composed of three
helical polypeptide chains that associate with one another
to form a right-handed triple helical structure (Prockop
and Kivirikko, 1984a) .

Type I collagen is a heterotrimer

composed of two al chains and one a2 chain.

Both types of

chains are synthesized as procollagen molecules consisting
of a triple helical segment flanked by amino and carboxy
terminal propeptides. The triple helical domain is
characterized by a regular Gly-X-Y repeating unit, where X
is often praline and Y is often hydroxyproline, although
they can be any amino acid except cysteine, tyrosine or
tryptophan (Kuhn, 1987) .

Collagen Formation
Helix formation begins at the carboxy end of the
chains and proceeds in a zipper-like fashion toward the
amino terminus.

The glycine residue in every third

position facilitates the folding of the three chains into
the triple helical conformation, which allows tight
6

7

association of the polypeptide chains.

During the helix

assembly in the rough endoplasmic reticulum, praline and
lysine residues are hydroxylated and some prolyl residues
are further glycosylated.

These post-translational

modifications continue until the completion of helix
formation (Byers, 1989; Prockop, 1984b), so the extent of
modification depends on the rate of helix formation
(Bateman et al., 1988).

Propeptides are enzymatically

removed by proteases after secretion from the cell into the
extracellular matrix (ECM) .

This allows the molecules to

spontaneously align into mature collagen fibrils which are
stabilized by covalent lysyl-derived crosslinks (Bornstein
and Sage, 1980; Kuhn, 1987).

The molecular crosslinking

also occurs in the mature molecule via disulfide bonding
between cysteine residues.
A compact, rigid triple helix is essential for tensile
strength in mature collagen fibers

(Byers, 1989).

Collagen

polypeptides are arranged in parallel stacks, and
crosslinked to form staggered microfibrils (Prockop, 1984)
Because post-translational modification is dependent on
the rate of helix formation, mutations in the Type I
collagen genes that result in a decrease in the rate of
triple helix formation often result in overmodification
(Bateman et al., 1986; Bonadio and Byers, 1985).

Post-

translational modification and intermolecular crosslinking
are both important in stabilizing the molecular arrangement
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within collagen molecules and between fibrils
et al., 1991).
packed.

(Kuivaniemi

In bone, collagen fibrils are densely

If a defective molecule is incorporated into the

uniform fibril environment, the strength of the tissue will
be compromised.

It causes not only instability in that

molecule, but all the adjacent molecules are affected.

It

would be less detrimental to produce fewer normal collagen
chains than to produce and incorporate a large number of
defective ones.

Type I Collagen Defects in OI
As a result of biochemical, molecular genetic, and
linkage studies, there is now little question that the vast
majority of patients with OI are heterozygous for mutations
in Type I procollagen (Sykes et al., 1990; Byers et al.,
1988c; Wenstrup et al., 1990).

More than 70 different

mutations in the two genes that encode the chains of Type I
collagen, the major protein of bone, have been identified
as the molecular cause of different forms of OI (Byers et
al., 1991).

The mildest forms of OI generally result from

overall production of Type I procollagen being synthesized
being decreased due to reduced synthesis of the pro al(I)
chain (Bateman et al., 1988). These defects may be due to
non-functional COLlAl alleles or ones that produce unstable
products (Willing et al., 1992).

Mutations in Type I

collagen genes which result in decreased rates of triple
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helix formation, cause overmodif ication of the protein
chains (Bonadio and Byers, 1985) which interferes with the
folding, processing and formation of stable collagen
molecules.

These unstable molecules are often rapidly

degraded and result in reduced amounts of collagen (Barsh
and Byers, 1981).

There are a number of cases that have

overmodif ied chains due to mutations in the sequence of the
triple helical domain (Bateman et al., 1988; Deak et al.,
1991; de Vries et al., 1986).

The mutations include point

mutations, insertions, deletions and re-arrangements in the
COLlAl gene that codes for the pro-al(I) chain and in the
COL1A2 gene that codes for the pro-a2(I) chain of Type I
collagen (Byers, 1990; Bateman et al., 1991).
The most commonly studied gene defects in OI are point
mutations which cause a substitution for a Gly residue in
the triple helix (Wallis et al., 1990; Cole et al., 1992).
These substitutions can also cause splicing defects which
can result in missing coding information (Kuivaniemi et
al., 1988).

Deletions can also cause splicing defects

(Tromp and Prockop, 1988) .

Occasionally insertions have

been observed that are responsible for frameshift mutations
(Willing et al., 1990; Genovese at al., 1989).

While the

detailed nature of the structural defects in the collagen
protein have been characterized in an increasing number of
OI cases, only occasionally have two cases been found to
have exactly the same biochemical defect (Rose et al.,
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1994; Prockop et al., 1994).

OI Types
Osteogenesis imperfecta is classified into four
different types based on clinical symptoms and the mode of
inheritance (Sillence et al., 1979b; Byers et al., 1987;
Prockop and Kivirikko, 1984a) .

OI Type I is a mild

dominantly inherited form (Sillence et al., 1979a; Byers et
al., 1988c; Prockop, 1984b) that involves defects in the
structure or synthesis of Type I collagen.

The clinical

features associated with Type I OI are bone fragility which
is reduced at puberty, blue sclerae, deafness and short
stature (Sillence, 1988) .

The triple helix in Type I cases

of OI are as stable as normal collagen or only moderately
unstable, and in some cases the helix stability is
explained by Type I mutations occurring in the X or Y
position of the Gly-X-Y sequence rather than in the glycine
position as occurs in Type II OI (Steinmann et al., 1986).
This may account for the milder phenotype (Bateman et al.,
1988a) .

There have been Type I OI patients found with

mutations that cause splicing defects with exon skipping in
the helical domain of the COLlAl gene.

The mild phenotype

may be a result of the deleted molecules not being
incorporated into the matrix (Superti-Furga et al., 1993;
Mattes et al. 1994).

In many OI Type I cases, even when no

structural defects have been identified, the total amount
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of Type I procollagen synthesized is low, due mainly to
reduced synthesis of the pro-al(I) chain (Byers et al.,
1988c; Bateman et al., 1988b).

Presence of non-functional

COLlAl alleles may be the cause of these defects (Willing
et al., 1992; Rowe et al., 1985).

By analysis of

restriction length polymorphisms (RFLPs), the phenotype has
been shown to consistently segregate with one or the other
Type I collagen genes (COLlAl or COL1A2)

(Tsipouras et al.,

1984; Falk et al., 1986; Sykes et al., 1990).

These

results clearly show that the defects in the structural
genes for Type I procollagen are responsible for this form
of OI.
OI Type II is the severe perinatal form that has been
well studied.

Its clinical characteristics include

neonatal dwarfism, severe bone deformity as a result of
multiple fractures and death in utero or shortly after
birth (Sillence, 1988) .

Most cases are the result of new

dominant mutations in the Type I collagen structural genes
which affect helix formation (Byers et al., 1988a; Byers et
al., 1988b).

Mutations have been found in both the COLlAl

and COL1A2 genes which results in substitutions for one of
the glycines of the triple helix.

The new substituted

residue is often cysteine or arginine (Vogel et al., 1987;
Bateman et al., 1988b) but valine (Patterson et al., 1989),
serine (Lamande et al., 1989) and aspartate (Baldwin et
al., 1989) substitutions have also been seen.

The
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substitutions are found at a number of positions throughout
the chains (Lamande et al., 1989; Baldwin et al., 1989;
Bateman et al., 1988b).

These results indicate that

mutations associated with the Type II phenotype are not
located in only particular positions of the helix.
Many cases appear to be point mutations that cause a
disruption in the regular Gly-X-Y sequence in the triplehelical domain which leads to an unstable helix that is
slow in forming and results in poor secretion of the
unstable procollagen molecule into the extracellular matrix
(Willing et al., 1988; Cohn et al., 1988b).

Since

modification of collagen chains occurs until a stable
triple helix is formed, Type I collagen chains usually
contain excess post-translational modification as a result
of the slowly forming helices in these cases (Byers et al.,
1988; Byers et al., 1988; Bonadio and Byers, 1985).

Other

mutations such as genomic deletions or point mutations in
the helical portion of COLlAl (Barsh et al., 1985; Chu et
al., 1985; Hawkins et al., 1991) or COL1A2 (Willing et al.,
1988) can lead to splicing defects and missing exons (Tromp
and Prockop, 1988) .
OI Type III is the progressively-deforming, moderately
severe form of OI.

It is deemed progressive in nature due

to repeated multiple fractures that result in severe
deformity of the limbs and spine.

Even though it is one of

the most common types, it is the least characterized
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(Sillence, 1988).

A few autosomal recessive cases exist,

yet most are due to spontaneously-occurring dominant
mutations (Thompson et al., 1988).

RFLP analysis of

several recessive pedigrees for Type III OI have shown that
this form is unlinked to either of the Type I collagen
genes (Byers et al., 1987; Aitchison et al., 1988).

A few

reports exist of substitutions and deletions in the Type I
collagen genes of OI Type III patients (Pihlajaniemi et
al., 1984; Byers et al., 1983a; Pack et al., 1989).

There

are also many cases where no such defects have been found
(Byers et al., 1988a; Beighton et al., 1988; Wenstrup et
al., 1990).

For these cases where no Type I collagen

mutation is present, defects in genes encoding bonespecific proteins or other ECM components could be
responsible for expression of the OI phenotype (Byers,
1990).
OI Type IV is the more severe dominantly inherited
form that also involves a variety of Type I collagen
defects (Sillence, 1988) .

Its clinical severity is

moderate, with patients having pale blue or white sclerae
and variable deformity of the long bones (Sillence, 1988) .
Amino acid substitutions at glycine positions in the triple
helical region of the a2(I) chain appear to be the basis
for many Type IV cases (Byers et al., 1988c; Wenstrup et
al., 1988).

RFLP analysis has shown that in many cases

this form of the disease segregates with the COL1A2 gene
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(Superti-Furga et al., 1989; Sykes et al., 1990).

The

kinds of defects found in Type IV are similar to those seen
in Type II OI.

This shows that the different forms of OI

cannot be distinguished by the collagen chain in which the
mutation occurs or even by the position of the mutation in
the chain.
It has not been possible to correlate specific defects
with particular OI phenotypes because there is still little
understanding of how defects in Type I collagen structure
cause the various types of OI.

Despite the large number of

studies of OI cases at the molecular level, the different
forms of the disease cannot be distinguished by which of
the two Type I collagen chains contains the mutation.

Even

when mutations map very closely to each other in the same
chain, they can be associated with OI phenotypes of widely
varying severity (Cohn and Byers, 1991).

There is very

little understanding of the functional domains of the
collagen molecule, which may add to the confusion in
determining correlations between defect and phenotype
(Sykes et al., 1990).

There are many cases where members

of a family carry the same Type I collagen defect and show
a wide variation of severity, even being asymptomatic
(Sykes et al. 1990; Superti-Furga et al., 1989).

Thus, the

variation in symptoms may involve other collagen types or
matrix proteins that interact with the various domains of
Type I collagen and thus affect the phenotype.

15
Collagen Types
At least seventeen kinds of collagen besides Type I
have been identified, but little is known about how they
contribute to the structural integrity of the extracellular
matrix (Mayne and Burgeson, 1987; Sandell and Boyd, 1990;
Shaw and Olsen, 1991; van der Mark et al., 1992).

They can

be classified into three main groups depending on their
structure.
Group one consists of the f ibrillar collagens (Types
I, II, III, V, and XI).

All members of the group have

similar structural features of being homo or heterotrimers.
They all contain three polypeptide chains, with a monomer
size greater than 95 kiloDaltons, and long uninterrupted
triple-helical domains containing the characteristic Gly-XY repeating amino acid sequence.

Most of the exons in the

helical coding regions of these genes are 54bp or multiples
of 54, and all of the exons in the helical coding regions
are multiples of 9bp in length, corresponding to integral
numbers of the basic Gly-X-Y repeat, beginning with the
codon for glycine and ending with a triplet preceding a
glycine codon (Sandell and Boyd, 1990; de Wet et al., 1987;
van der Mark et al., 1992).

The genes for these collagens

share a highly conserved exon-intron organization.

The

coding sequences are divided into nearly identical numbers
of exons, and all intrans regardless of size, are located
in homologous positions in each gene (Sandell and Boyd,
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1990; Fleischmajer et al., 1990).
Type III collagen is often present in minor amounts in
the same fibrils with Type I. Small amounts of Type V
collagen are also associated with Type I fibrils and
occasionally with Type II fibrils
1987).

(Mayne and Burgeson,

Type v and XI are more similar to each other

structurally than any other two collagens (Greenspan et
al., 1991).

Type XI is expressed in all cartilage tissue

and may be associated as a minor component with the Type II
fibrils that make up those tissues (Mayne and Burgeson,
1987).
Group two consists of the large nonfibrillar Types IV,
VI and VII.

They all have monomer chain sizes of greater

than 95 kiloDaltons with large globular domains, and a
number of interruptions in the repeating Gly-X-Y repeat
within the triple helical domains (Mayne and Burgeson,
1987; Sandell and Boyd, 1990; Parente et al., 1991).

These

interruptions allow the molecules flexibility which is not
possible in the fibrillar collagens (Hoffman et al., 1984).
Types IV and VI are heterotrimers, while Type VII is
believed to be a homotrimer (Fleischmajer et al., 1990).
This group is not well characterized; only the genes for
the two chains of Type IV and three chains of Type VI have
been studied in detail.

Their exon sizes and overall

intron-exon patterns are completely different from the 54bp
exon pattern of the fibrillar collagens (Soininen et al.,
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1988; Soininen et al., 1989).

These collagens aggregate

through end-to-end associations of monomer units rather
than by lateral association (Timpl et al., 1981).
The function of Type IV collagen in the matrix is not
understood.

It is found in basement membranes and

interacts weakly with cell membranes, laminin and
proteoglycans.

Type VI collagen may serve as a link

between other matrix components and cells, yet does not
appear to be physically associated with the major fibrillar
elements in extracellular matrices.

Type VII seems to link

the basal surface of epithelial cells with the dermis as
part of the anchoring fibrils, but the biochemical basis
for this is unclear (Mayne and Burgeson, 1987; Fleischmajer
et al., 1990).
Group three consists of the short-chain Types VIII,
IX, X, XII, XIV and XVI. These collagens all have monomer
chains of less than 95 kiloDaltons with many interruptions
in the Gly-X-Y repeat of their triple helical domains
(Sandell and Boyd, 1990) .

This collagen group shows great

variation in gene structure.

Two chains of Type VIII and

one of Type X have been characterized, and they show common
structural features, that consist of 8 interruptions of the
helix with similar sequence, length and relative location
(Yamaguchi et al., 1989; Muragaki et al., 1991).

Both

Types IX and X contain short collagenous domains, yet the
5kb gene for pro-al(X) collagen contains only 3 exons and
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no intrans in its triple helical coding sequences (Sandell
and Boyd, 1990).

The genes for pro-al(IX) and pro-a2(IX)

have been partially characterized and only a few 54bp exons
have been found in either of them (Sandell and Boyd, 1990;
Ninomiya et al., 1990).

Type VIII collagen is found in

basement membrane of corneal endothelial cells and Type X
in the endochondral ossification zones of cartilage
(Muragaki et al., 1991; Reichenberger et al., 1992).
Types IX, XII, XIV and XVI have been grouped into a
subgroup called FACIT collagens (fibril-associated
collagens with interrupted triple helices) to emphasize
their homologous structures and possible function (Shaw and
Olsen, 1991) .

The molecules in this class contain more

than one triple-helical domain separated by non-triplehelical segments (Shaw and Olsen, 1991) .

The FACIT

proteins are associated with fibrils composed of f ibrillar
collagens.

FACITs all share structural features, yet their

sizes and primary structures vary greatly (Pan et al.,
1992) .

They may be important in the organization and

stability of extracellular matrices.
Type IX collagen is found in cartilage and is arranged
in a periodic fashion along the surface of the major
fibrils made up of Types II and XI (Shaw and Olsen, 1991) .
The globular domain of Type IX projects out of the surface
of the major fibril possibly facilitating interactions
between the major fibril and other molecules of the matrix
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(Shaw and Olsen, 1991).

Type XII, with a structure

homologous to that of Type IX, is found primarily in
tissues where Type I is the major fibrillar collagen.
Although Type XII co-localizes with Type I in many tissues,
it is not found in skin or bone (Shaw and Olsen, 1991) .
Another recently discovered collagen, Type XIV, is found in
skin and, since it is homologous to Types IX and XII it may
interact with the major fibrils composed of Types I and V
(Shaw and Olsen, 1991; Dublet and van der Rest, 1991).
Both types XII and XIV localize near the surface of banded
collagen fibrils and influence interaction between adjacent
fibrils as-well-as participate in extracellular matrix
deformability (Nishiyama et al., 1994).

Type XVI collagen

is made by fibroblasts and keratinocytes (Pan et al.,
1992).

It has structural similarities to Types IX and XII

(Pan et al., 1992).
New collagen loci continue to be discovered and
characterized. The newly identified Type XIII gene has a
helical-coding domain made up of several 54bp exons and a
number of other exons with unrelated sizes (Tikka et al.,
1991) .

This gene has both fibrillar and non-fibrillar gene

characteristics.

The collagen structure it codes for

resembles that of the FACIT collagens.

More new collagen

types include XV, XVII and XVIII that are characterized by
many short triple helical domains, unlike the long,
contiguous domains found in the other collagen types.

Type
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xv

is found in kidney and pancreas and Type XVII is found

in hemidesmosomes, yet the function of these collagens is
still unknown (Muragaki et al., 1994).

BPAG2 is yet

another new collagen and is found in stratified squamous
epithelia.

It contains both collagenous and non

collagenous domains.

Its exon organization is different

from any other f ibrillar or nonf ibrillar collagen genes (Li
et al., 1991).

Newly-Identified Collagen-Like Loci
Recent studies have identified two undescribed
collagen-like loci that are different from other already
characterized collagen genes (Doering et al., 1993).

The

loci were detected with a pro-a2(I) cDNA probe (Doering et
al., 1993).

The normal restriction fragments containing

Site 1 are a 7.4kb Hind III that contains a 3.0kb Pst I
fragment.

Site 2 is detected in normal individuals as a

4.6kb Hind III fragment that overlaps a 5.2kb Pst I
fragment and is localized to chromosome 17 (Doering et al.,
1993).

This site has been cloned from a chromosome 17-

specific lambda phage library and a restriction map has
been constructed (Cammarata et al., 1991).

The 4.6kb

HindIII fragment was isolated and the triple helical coding
region within it was characterized by restriction mapping
and sequencing (Cammarata, 1994) .

Determining the detailed

molecular organization of this locus is the inital step
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necessary to characterize the structure, and function,

of

the putative protein that is coded for by the new locus.
Recent studies of the new collagen-like loci suggest
that deletion sites could be contributing to the OI
phenotype.

Deletions that are heterogeneous in size and

occur in a spontaneous fashion have been detected at these
sites in genomic DNA of Type III OI patients (Breslin et
al., 1995; Cammarata et al., 1991; Doering et al., 1987).
While these deletions do occur in normal individuals they
are much less frequent there and less heterogeneous in size
(Doering et al., 1990; Cammarata et al., 1993).

Because of

a very low frequency of heterozygote deletions at Site 2,
the alleles there are not in Hardy-Weinberg equilibrium.
This is important because it suggests that Site 2 is at a
locus that is expressed and that its genotype may result in
a disadvantageous phenotype that selection will operate
against.

The new loci may code for a connective tissue

component(s) which, when defective, contributes to the OI
phenotype (Doering et al., 1993).

It is suggested that the

disease phenotype requires an interaction between Type I
collagen and the products of other loci, as suggested by
the many examples of asymptomatic individuals carrying the
same Type I collagen as their family members who have OI
(Cohn and Byers, 1991; Constantinou et al., 1989; Hollister
et al., 1988).

The deleted alleles at Site 2 may not cause

the disease directly, but the defective product of the
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locus may interact with other mutant connective tissue
components to produce the OI phenotype.

The deletions in

patients then may act independently or by modulating the
effect of Type I collagen defects.
Length polymorphisms where insertions/deletions change
the length of DNA loci have been shown to be caused by
various kinds of repetitive sequences (Sykes et al., 1985;
Lee et al., 1991; Sykes et al., 1990).

Tandemly-repeated

sequences normally cause the length polymorphisms (Caskey
et al., 1992).

Direct repeats have also been shown to be

involved in causing deletions within collagen genes (Chu et
al., 1985; Sykes et al., 1985; Hawkins et al., 1991).
Fascioscapulo-humeral muscular dystrophy (FSHD) has
recently been shown to be associated with deletions in a
tandemly repeated sequence (van Deutekom et al., 1993;
Winokur et al., 1994).

In fragile X syndrome, myotonic

dystrophy and Huntington's disease, variable numbers of
tandemly-repeated sequence cause longer polymorphisms in
the alleles of affected individuals.

There is also a range

of premutation alleles in a range between that of normal
and affected individuals seen in individuals with these
diseases (Caskey et al., 1992; Sutherland and Richards,
1995) .

These alleles may cause mild or no disease symptoms

in the individual carrying them, but long alleles arise
spontaneously in their affected children (Caskey et al.,
1992).

The parental deletions we have observed in OI
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families may give rise to further spontaneous deletions in
their children, which then could contribute to the OI
phenotype.

The mechanism responsible for the instability

and frequent deletions at Site 2 may be similar to that of
these other diseases that are associated with unstable
tandem repeats.
By determining the molecular organization of deletions
at Site 2 in OI patients it may be possible to determine
the mechanism responsible for the frequent deletions.

The

deletion location in Site 2 was determined and then
sequenced in deleted and undeleted alleles to define
deletion sizes, endpoints and the involvement of tandemly
repeated sequences.

These studies will ultimately provide

understanding as to how the abnormalities caused by the
deletions contribute to the OI phenotype.

CHAPTER III
MATERIALS AND METHODS

Experimental Approach
The purpose of this study was to localize and
determine the molecular organization of the deletion site
in one of the new collagen-like loci (Site 2).

To

characterize the deletions in the Site 2 locus (4.6kb
HindIII fragment), the location of the deletion was
determined.

The Site 2 clone was used to probe blots of

restriction digested normal and patient DNAs, to
approximately localize the deletions within the 4.6kb site.
Sequencing of the cloned normal locus in the region where
deletions occur was done to determine the nature of the
sequence.

Primers for PCR reactions were then chosen from

non-repetitive, non-complementary sequences in this region.
PCR was then done on patient DNAs to isolate the deletion
region and to allow its sequencing.

The molecular nature

of the deletions was then determined by comparing the
sequence of a short allele in an OI patient to the normal
allele. This was done in order to determine the deletion
endpoints and possible mechanism(s) responsible for the
deletions.
24
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Restriction Enzyme Digests
To localize the deletion site within the locus, DNA
was restriction enzyme digested by established methods
using single and double enzyme combinations (Doering, 1977;
Peterson et al., 1980; Rosenthal et al., 1984).
Restriction enzymes with sites in the 4.6kb (Site 2) clone
were used to digest DNAs from a normal individual and from
a patient with a homozygous 200bp deletion at Site 2.

A

comparison of the fragment sizes obtained in the control to
that of the patient was done to localize the deletion.

The

smallest region where the fragment sizes are different
between the normal and patient allowed this localization.
All restriction enzymes were purchased from Bethesda
Research Laboratories (Bethesda, MD) and used in the
supplier's recommended buffers.

Restriction digests were

stopped by adding 0.5% SDS and lOmM EDTA.

Gel

electrophoresis was carried out on 0.9% agarose gels
(Rosenthal and Doering, 1983) and the DNA transferred to a
nylon membrane (Gene Screen Plus hybridization membranes;
NEN Research Products, Boston, MA) using the alkaline
transfer method (Reed and Mann, 1985) .

The DNA size

markers used were lambda phage DNA digested with HindIII
and ¢-X 174 phage DNA digested with HaeIII.
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Nick Translation and Hybridizations
The method for locating the deletion involved using
the Site 2 radiolabeled clone as a probe to compare
restriction fragment sizes obtained in a normal control to
that in a patient with the deletion.

The EcoRI/SstI

fragment of the Site 2 clone P4.6 (Cammarata, 1994), which
contains no repetitive sequences was
translation (Rigby et al., 1977).
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P-labeled by nick

Prehybridization of the

membrane was carried out for at least 5 hours at 37°C with
agitation (Doering et al., 1982; Rosenthal and Doering,
1983) in 40ml of hybridization solution (50% formamide,
0.9M NaCl, 50mM Tris pH 7.5, 1% sodium dodecyl sulfate,
lOµg/ml denatured E. coli DNA).

Denatured nick translated

probe (6ng/ml) was added to the prehybridized membranes and
incubation proceeded at 37°C for a minimum of 16 hours with
agitation.

Membranes were washed twice at room temperature

for 30 minutes in 2X SSC (lX SSC is 150mM NaCl, 15mM sodium
citrate, 0.1 mM EDTA); twice at 60°C for 30 minutes in 2X
SSC with 1% SDS; and lastly, twice at room temperature for
30 minutes in 0.5X SSC.

Autoradiography was then done

using Kodak XAR x-ray film and Dupont Lightning-Plus
intensifying screens as necessary.
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DNA Sequencing
To determine the sequence in the deletion site, DNA
sequencing of the Site 2 subclone P4.6ME (Cammarata, 1994)
was done by the dideoxy method (Sanger et al., 1977) using
the "AmpliTaq" kit (Perkin Elmer Cetus, Norwalk, CT).

The

double-stranded template and primer were denatured and
reannealed as follows prior to extension/termination
reactions.

Three micrograms of template DNA and O.Spmol

primer DNA were combined in a total volume of 20.0µl.

NaOH

and EDTA were added to a final concentration of 0.2M and
0.2rnM respectively, and the mixture was incubated for 5
minutes at 85°C.

The tube was placed on ice, and 6.0µ1 of

3M NaOAC, pH 5.2 and 60µ1 100% EtOH were added to
precipitate the denatured DNA.
-20°c for 20 minutes.

This solution was placed at

The DNA was pelleted by

centrifugation at 9,500rpm in an SHMT rotor (Sorvall/E.I.
duPont, Newtown, CT) for 20 minutes and washed carefully
with 70% EtOH.

The dried DNA pellet was resuspended in

14ul distilled H2 0 and reannealed for 5 minutes at 37°C
followed by 7 minutes at room temperature.
The extension and termination reactions were carried
out according to the manufacturer's instructions for
sequencing double stranded DNA using the "Amplitaq"
sequencing kit (Perkin Elmer Cetus, Norwalk, CT).
was tagged by adding
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The DNA

S-labelled dATP nucleotides during

the extension reaction.

The T7 primer was used and
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extension began from the Eco RI site, or in the case of the
nested deletion clones, sequences adjacent to this site,
and proceeded to the left through the helical coding
region.
The sequence that was determined was highly repetitive
and internal primers would not allow reading far enough
into the sequence.

Subclone deletions of the DNA fragment

of interest were generated in order to facilitate reading
far enough into the sequence to locate the deletion region.

Generation of Nested Deletions
Nested deletions were generated using the "Erase-aBase" system (Promega Corporation, Madison, WI) according
to the manufacturer's instructions.

In order to sequence

the region where the deletions occur, the Site 2 subclone,
P4.6ME, was cloned into a pGEM7Zf+ vector (Promega Biotech,
Madison, WI), and digested by exonuclease III digestion
from the Eco RI site, with samples being removed at timed
intervals.

Sl nuclease treatment was done to remove single

stranded tails left from digestion.

The Sl nuclease was

neutralized and heat inactivated, and Klenow DNA polymerase
was added to generate blunt ends which were ligated to
circularize the plasmids for transforming competent cells
(Sambrook et al., 1989).

The deleted subclones were

screened by doing plasmid mini-preps (Mierendorf et al.,
1978) to determine subclones of the appropriate size (see

29
Figure 3).

Overlapping subclones at intervals that were

far enough into the region were sequenced (P4.6ME-9,
P4.6ME-13, P4.6ME-18).

Sequence analysis was done with

standard computer programs (Vasios et al., 1987).
Sequences in the region of the deletion site allowed the
construction of DNA primers for PCR reactions.

The

sequences necessary for primers are non-repetitive, noncomplementary sequences of approximately 20-25bp long
(Innis et al, 1990).

Polymerase Chain Reaction
Sequence analysis of the P4.6ME subclone sequences was
done with the aid of the Genetics Computer Group sequence
analysis program, version 7.1 (Devereux et al., 1984), and
20bp primers (4.6-1: GGAGACACGAGCCACTCAAG, 4.6-2:
AGAGAACCCCCTCCAAGAGC)

that flanked the region of the

deletion were generated by the Macromolecular Analysis
Facility (Loyola University Chicago, Maywood,

IL) .

The

primers were used in the polymerase chain reaction (PCR) to
amplify the sequence around the site of the deletion
region.

PCR reactions were optimized using the Bios

Optimization System (Bios Laboratories, New Haven, CT) and
consisted of 10µ1 of lOx Optitaq buffer G (40mM NaCl, lOmM
Tris-HCl, pH 8.4, 0.01% gelatin, 0.1% Triton X-100, 1.SOmM
MgCl 2 ) or 0

(lOrnM (NH4 ) 2 S0 4 ,

lOmM KCl, lOmM Tris-HCl, pH

8.4, 0.01% gelatin, 0.1% Triton X-100, 3.75rnM MgCl 2 )

(Bios
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Laboratories, New Haven, CT)

, lOµM of each primer, 1.06µ1

dNTP mix which contained 20mM of each deoxyribonucleotide:
dGTP, dATP, dTTP and dCTP (Bias Laboratories, New Haven,
CT), 4ng template for p4.6EP and 0.5ug template for patient
DNA, 2U Taq DNA polymerase (Perkin Elmer Cetus, Norwalk,
CT) and dH 2 0 to 100µ1.

PCR was carried out in an MJ

Research Programmable Thermal Controller using a profile
of: 94°C for 1 minute (denature), 64°C for 1 minute
(anneal), 72°C for 1 minute (extend) for a total of 35
cycles.
In PCR products of patient DNAs, two bands resulted in
those patients who were heterozygous for the deletion.
Only one of the regions was the area of interest for
sequencing.

In order to isolate that one band, band-stab

PCR was utilized (Kadokami et al., 1994; Bjourson et al.,
1992).

PCR reactions consisted of 10 µl of lOx Optitaq

buffer G or 0 (Bias Laboratories, New Haven, CT), lOµM of
each primer, l.06µL dNTP mix (as above), 2U Taq DNA
polymerase and dH 2 0 to 100 µl.

The template for these

reactions was acquired as follows: an aliquot of the twobanded PCR product was run out on a 1.5% agarose gel.

The

gel was stained with ethidium bromide, and viewed on a UV
transilluminator (300nm) .

Excess water was removed from

the surface of the gel with Whatman 3MM paper and the
appropriate band was stabbed or lifted out of the gel with
a hypodermic needle which was then dipped with gentle
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agitation into a fresh PCR reaction mixture.

PCR was

carried out under the same conditions as above.

Cycle Sequencing
PCR products were prepared for sequencing using the
"wizard" PCR clean-up method (Promega Corporation, Madison,
WI).

Thermal cycle sequencing using the "fmol" kit

(Promega Corporation, Madison, WI) and the dsDNA Cycle
Sequencing system (Life Technologies, Inc., Gaithersburg,
MD) were done following the manufacturer's instructions
which involved a two-step process to prepare the samples
for PCR.
The dsDNA Cycle Sequencing system first step is
labeling the primer:

lpmol of primer, 2pmol of

r 32 P ATP,

1.0 µl 5x Kinase buffer, and 1.0 unit of T-4 kinase and
dH 2 0 to 5µ1 were mixed and incubated in a 37°C waterbath
for 10 minutes; the kinase was then deactivated at 55°C for
5 minutes.

The reaction mixture consisted of: 5.0 µl

labeled primer, 4.5µ1 lOx sequencing buffer,

.033ng

(50fmol) of template DNA, 1.23 units Taq polymerase and
dH 2 0 to 36µ1.

8µ1 of this mixture were added to tubes

containing 2µ1/tube of appropriate termination mix: ddGTP,
ddATP, ddTTP or ddCTP.

The tubes were overlaid with

silicone oil and spun.

After PCR was completed 5µ1 of stop

solution was added and the tubes spun.
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The fmol kit started by labeling the primer:

5pmol

primer, 5pmol y 32 P ATP, 0.5µ1 lOx kinase buffer, and 2.5
units of T-4 kinase to 5µ1 was mixed and incubated in a
37°C waterbath for 30 minutes; the kinase was then
deactivated at 90°C for 2 minutes.

The reaction mixture

consisted of: 1.5µ1 labeled primer, 5.0µ1 5x fmol buffer,
235.3ng (500fmol) of template DNA and dH 2 0 to 16µ1.

To

this tube 1.25 units of Taq polymerase were added, then 4µ1
were added to tubes containing 2µ1/ tube of appropriate
termination mix: ddGTP, ddATP, ddTTP or ddCTP.
were overlaid with silicone oil and spun.

The tubes

After PCR was

completed 3µ1 of stop solution was added and the tubes
spun.
PCR was carried out for either method in an MJ
Research Programmable Thermal Controller using a profile
of: a 95°C "hot-soak" for 3 minutes, 95°C for 30 seconds
(denature) , 62°C for 30 seconds (annealing) , 72°C for 1
minute (extension/ termination), repeating the
denature/annealing/ extension/termination steps for 19
cycles, then 95°C for 30 seconds (denature), 70°C for 1
minute (extension/ termination), repeating this for 9 more
cycles. The above two methods were utilized to sequence the
deletion sites in the P4.6 clone and a patient with a short
deletion.

Comparison of the sequences of the short allele

and the normal allele were then made.
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Sequencing Gels
Sequencing gels containing 8% acrylamide/bis (37.S:l)
and 7M urea were used to obtain the sequencing data.

To

prepare the gel for casting, glass plates were cleaned
using "clear Ivory" dishwashing detergent and rinsed with
tap water.

Excess water was removed by rinsing the plates

with 9S% ethanol.

The larger plate was then silanized

using either Rain-X (Unelko Corporation, Scottsdale, AZ) or
Gel Slick (AT Biochem, Malvern, PA) following the
manufacturer's instructions to allow for easy separation
following electrophoresis.

One hundred twenty five mls of

the 8% acrylamide/bis and urea mixture was filtered and
degassed. Immediately before pouring, 800µ1 of fresh 10%
ammonium persulfate and 20µ1 of TEMED were added to the gel
mixture.

The gel was poured between the plates using a

60ml syringe and 18 1/2 gauge needle.

The gel was run

using lxTBE buffer and SSW of constant power.

After

electrophoresis, the sequencing gel was soaked for lS
minutes in 10% glacial acetic acid/10% methanol to remove
the urea.

The gel was then transferred to Whatman 3MM

filter paper by established methods (Kozak et al., 1991),
dried in a gel dryer (Bio-Rad laboratories, Hercules, CA)
for 3 hours, 20 minutes and autoradiographed.

The sequence

was read a minimum of 3 times from independent gel runs in
order to confirm the sequence accuracy.

Sequence analysis

was done with the aid of the VAX network system (Loyola
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University Chicago), the Genetics Computer Group sequence
analysis program, version 7.1 (Devereux et al., 1984), and
the Hibio DNAsis DNA sequence analysis system, seventh
version (Hitachi, 1990).

CHAPTER IV
RESULTS
Localization of Deletion in Site 2
The first step in characterizing the Site 2 locus (4.6kb
Hind III fragment) was to approximately localize the region
where the deletions occur.

A genomic clone containing Site

2 (p4.6) has previously been isolated (Cammarata, 1994), and
its

restriction

EcoRI/SstI

map

is

shown

in

Figure

fragment of this clone was
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1.

The

1. 4kb

P-labeled by nick

translation and used to probe blots of restricted genomic
DNAs from two different normal heterozygous individuals and
a patient with a homozygous 200bp deletion at Site 2.

Single

and double digest combinations were performed in order to
delimit the deletion site.

A single digest using Hind III

was done, as well as various double digests, working inward
toward the helical coding region

(Figure 1) .

Smaller and

smaller regions were digested to narrow down the location of
the deletion.

The goal was to locate where the fragment in

the patient and the normal become the same size.

The Hind

III digest resulted in one fragment of 4.4kb in the patient
and two fragments of 4. 6kb and 4. 3kb respectively in the
normal

(Figure 2A,

lanes 9 and 10).

The Hind III+Pst

I

digest resulted in one fragment of 3.7kb in the patient and
35
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two

fragments

individual

of

sizes

3. 9kb

and

3. 6

kb

in

the

normal

The Hind III+PvuII

(Figure 2A, lanes 7 and 8) .

digest resulted in one fragment of 2.8kb in the patient and
two

fragments

of

sizes

3.0kb

and

individual (Figure 2A, lanes 5 and 6) .

2.7kb

in

the

normal

In the second set of

digests, done to confirm the data, one fragment of 2.8kb in
the patient and two fragments of sizes 3.0kb and 2.7kb were
also seen in the normal (Figure 2B, lanes 3 and 4) .

The Hind

III+EcoRI digest resulted in one fragment 2.3kb in size in
both the patient and normal (Figure 2A, lanes 3 and 4) .

The

second set of digests resulted in one fragment of 2.3kb in
both the patient and normal (Figure 2B, lanes 1 and 2).

The

HindIII+BglI digest resulted in one fragment 2.0kb in size
for both the patient and normal (Figure 2A, lanes 1 and 2).
The deletion was determined to be in the region between the
EcoRI and PvuII sites.

This is the region where the second

allele,

the deletion is

which contains

lost.

The PvuII

digest still had two bands and a smaller patient band, but in
the Eco digest the bottom normal band is lost and the normal
and patient band become the same size.

This region contains

the triple helical-like coding region of Site 2 (see Figure
1)

(Cammarata, 1994) .

Because of the collagen-like nature of

this region, and the fact that deletions can occur here, the
region was sequenced to determine its characteristics.
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Sequencing of the 4.6 Subclone
At

Site

2,

deletions

of

heterogeneous

size

are

significantly more prevalent in OI Type III patients than in
unaffected individuals
al., 1987).

(Cammarata et al.,

1991; Doering et

Because the above results showed the deletion

was located in the collagen-like helical coding region of
Site 2

(see Figure 1) the detailed sequence of this region

is important to know.

Previous characterization of 735bp of

this region found it to be repetitive in nature and very GC
rich

(Cammarata, 1994) .

the entire region.

This led to problems in sequencing

A "ladder" effect from all the secondary

structure resulted when trying to sequence farther in than
200bp from the primer.

Internal primers based on the new

sequence usually allows for further sequence determination
and helps reduce the premature termination that results from
secondary structure.

However, the repetitive nature of the

sequence (Cammarata, 1994) did not allow for identification
and use of internal primers.

To allow for sequencing, the

EcoRI/SmaI fragment was isolated and subcloned as a 1.Skb
EcoRI/SmaI

fragment

into a

pGEM7Zf+ vector

(P4. 6ME)

(see

Figure 3C), so that nested deletions could be generated to
allow sequencing of the entire region extending beyond 735bp
to 899bp, which is the entire repeat region.
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Generation of Nested Deletions
The
Corporation,

WI)

allowed

serial

EcoRI

digested

end

Madison,

nucleotides

from

system

"Erase-A-Base"

the

(Promega
removal

of

the

of

P4.6ME

A series of clones is

subclone by employing exonuclease III.

created by removing samples at timed intervals which bring
the 3' sequences closer to the primer.

This method allowed

the creation of a series of subclones containing overlapping
sequences

that

encompassed

the

remaining portion of

triple helical coding region (see Figure 3D) .

the

The deletion

subclones P4.6ME-9 (325bp), P4.6ME-13 (225bp), and P4.6ME-18
(175bp) were used to generate the nucleotide sequence from
position 535
remainder

of

through to position 899
the

helical

coding

which

region.

includes

the

Sequence

was

obtained using the "Ampli-Taq" sequencing kit (Perkin-Elmer
Cetus) .

This

polymerase,

kit

was

utilized

because

it

which is a very heat stable enzyme

uses

Taq

(45-72°C),

which was needed to reduce secondary structure in the GC rich
areas.

Figure

4

shows

a

representative

example

of

the

sequence information obtained from 8% acrylamide sequencing
gels of the subclones.

The sequence generated by the above

methods will be referred to as "NT899"

(see Figure 5) .
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Results of the Sequencing Data

The nucleotide sequence.

Analysis of the sequence shows

that from position 128 to 775 there are 34 direct repeats
composed of the consensus 18 nucleotide repeating unit: AAG
ACC AGC AGC CCA GAC.
average

of

93.3%

Each of the repeating units have an

identity

substantial heterogeneity.
that are

to

this

sequence,

yet

have

There are three interruptions

9 nucleotides long,

and these insertions,

which

disrupt the direct repeats, begin with a PvuII restriction
site

(indicated

by

carats

and

underlined

in

Figure

6).

Although these insertions interrupt the direct repeats, their
presence results in the coding of two perfect triple helical
9-mers with the amino acid sequence (Gly-X-Y)
translation at these locations.
insertions which interrupt

2

in the reverse

There are also thymidine

the direct

repeats

at various

locations in the NT899 sequence (see Figure 6) .
The basic repeating unit is not itself a strict triplet
repeat sequence,

but by substituting "C"

fourth position it becomes one.
this subs ti tut ion though.

for

"A",

in the

Very few repeats contain

On the occasions when it does

occur, a "T" insertion also occurs in that repeat making it
19bp long.

In the repeats with "T" insertions subsequent to

a PvuII site, two perfect triplet repeats adjacent to each
other also occur.

These are also in the reverse translation.

Sequence analysis.
shows

there

is

Computer analysis of the sequence

63% GC content,

which is

consistent with
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collagen sequences (Bernard et al., 1983).

Analysis of the

helical coding region sequence was performed with the aid of
the GCG "bestfit", "overlap" and "fasta" programs (Devereux et
al.,

1984).

This allowed sequences to be chosen for DNA

primers for PCR reactions.

The desired primers would flank

the repetitive region to allow amplification of the deletion
region (see Figure 6) .

The sequences necessary for primers

are

non-complementary

non-repetitive,

sequences

of

approximately 20-25bp in length (Innis et al., 1990).
Fifteen primers were originally chosen from the regions
flanking the repeat clusters of NT899 for analysis.

The

bestfit program was used to make an optimal alignment of the
best segment of similarity between each primer and NT899.

It

does

of

this

by

inserting

gaps

to

maximize

the

number

matches.

You want a primer with the smallest number of

bestfits,

so

it will

not be

places in the sequence.

complementary with multiple

Both strands of the sequence are

searched using this method.

You can thus also determine that

the primer will amplify in the proper orientation (5' or 3'),
most efficaciously.
Once the primers are narrowed down by bestfit, you run
them on the overlap program.

It compares two sets of DNA

sequences to each other in both orientations looking for
overlaps between sequences
similarity

(see Figure

overlap found,

7) .

rather than simply regions of
The lower the percentage of

the safer it would be to say that you have
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only one site that would bind the primer.

Anything below 50%

overlap is considered acceptable (Devereux et al., 1984).

If

possible, overlap should not be on the end of the primer in
the orientation of amplification,
misamplification.

Also,

complementary orientation,

if
it

to avoid the risk of
the

is

overlap

not

that

is

big a

in

the

concern

because you will only be amplifying or sequencing in the
direction for which the primer was chosen.
The final check of the primers was to run a
analysis.

This

searches

for

sequence and any other sequence,

similarities

length of

fas ta 11

between

one

aligning the search set

against the query set for display Figure 7)
the

11

overlap and minimizes

It optimizes

gaps

to

only a

few

nucleotides, finding the portion of sequence with the highest
identity.
and 4.6-2:

The resulting primers 4. 6-1: GGAGACACGAGCCACTCAAG
AGAGAACCCCCTCCAAGAGC flanked the region of the

deletion (see Figure 6) .

These primers were chosen because

they had the lowest amount of overlap to the NT899 sequence
in

the

orientation

for

amplification,

had

no

repetitive

sequence, and had the least match to the NT899 sequence- in
the complementary orientation.
Primer 4.6-1 was located between bp88 and 107 of NT899
(see bold underlined primer in Figure 6) .

Analysis of the

first primer showed it had only 28-30% overlap to any site in
the NT899 sequence in the forward direction, except for one
site with 40% overlap.

None of the regions of overlap were
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on the end of the primer.
in

the

reverse

It had one region of 30% overlap

(non-amplifying)

direction.

This

was

acceptable since PCR and DNA sequencing would only be in the
forward direction (left to right in Figure 6)
reverse direction with this primer.

and not the

Primer 4.6-2 was located

between bp781 and 800 of NT899 (see bold underlined primer in
Figure 6)
overlap

Analysis of this primer showed it had only 30-35%
to

any

sites

in

the

NT899

sequence

in

amplification direction (right to left in Figure 6)
one

region

of

30%

overlap

on

the

opposite

its

It had

strand

(non-

amplifying direction) that was within the primer, not on the
end.

This was acceptable since this primer would only be

used

to

generate

PCR

products

amplification direction.

and

DNA

sequence

in

the

The primers had no overlap with

each other (data not shown) .

PCR of the p4.6EP Subclone Repeat Region
The primers were used in the polymerase chain reaction
(PCR) to amplify the sequence around the site of the deletion
region in the p4.6EP subclone.

PCR reactions were optimized

using the Bias Optimization System (Bias Laboratories, New
Haven,

CT)

3. 7 5mM)
(NH 4 ) 2 80 4

which varies

Mg++

the

(range

in three different buffers based on KCl,
•

O. 75-

NaCl or

Mg++ concentration is a key variable in controlling

specificity and yield of PCR.
by

concentrations

buffer

is

also

The ionic environment provided

critical

to

the

specificity

of
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amplification.
profile

Amplification

specific

to

the

proceeded
locus

with

and

a

thermal

products

were

electrophoresed on agarose to select the buff er yielding the
optimum balance of specificity and yield (data not shown) .
Buffers G(40mM NaCl, lOmM Tris-HCl, pH 8.4, 0.01% gelatin,
0 .1% Triton x-100,

1. 50mM MgCl 2 )

or 0 (lOmM

(NH4 ) 2 80 4 ,

lOmM

KCl, lOmM Tris-HCl, pH 8.4, 0.01% gelatin, 0.1% Triton X-100,
3.75mM

MgCl 2 )

Reactions

were

used

contain 4ng of

to

amplify

the

repeat

the p4. 6EP clone DNA,

region.
which is

amplified with Taq polymerase using the following profile:
94°C for 1 minute, 64°C for 1 minute, 72°C for 1 minute, for
35 cycles.
The p4.6 site 2 clone was amplified first to make sure
the primers were specific and resulted in the proper size
fragment.

The resulting fragment was approximately 790bp

long (see Figure 8, lane 3).

This is the same size as the

tandem repeat region flanked by the chosen primers.

Genomic

DNA from an unaffected individual was then amplified.

Two

fragments resulted, one 790bp in size and one 500bp in size
(see Figure 8,

lane 2) .

The smaller fragment is the one

containing the deleted region.

This verified the results

from the Southern blots in Figure lA and B,

that there are

two alleles in the normal individual and one contains an
approximately 300bp deletion in the triple helical coding
region.
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PCR of Patient DNA
The constructed primers were then used to amplify the
repeat region from the genomic DNAs of five additional OI
patients known to have Site 2 deletions, three of which are
shown here (see Figure 8, lanes 4, 5 and 6).
five

patient

heterozygous
region.

DNAs
or

that

were

homozygous

PCR

for

Four out of the

amplified

deletions

in

were

either

the

repeat

A possible explanation for the patient with only one

full-length band could be that the deletion region expanded
outside the tandem repeat region or may be located elsewhere
in the Site 2 gene. Deletions at the site result in shorter
than normal
result,

fragments being generated by the PCR.

As a

comparing the sizes of the DNA fragments generated

from each sample permits identification of individuals with
a deletion and indicates what size deletion they have.
patient

(lane

6)

was

approximately 200bp.

homozygous

for

a

deletion

of

The range of sizes of the deletion in

the three heterozygous patients from 60-340 bp in length.
all cases but one,

One

In

shorter than normal fragments resulted,

indicating that Site 2 deletions are usually confined to the
region containing the tandem repeat clusters.

Direct Sequencing of PCR Products
In order to sequence PCR products, they must be free of
contaminating amplification primers and nucleotides.

The

wizard PCR preps DNA purification system (Promega, Madison,
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WI)

was used to prepare PCR products for sequencing.

purifies

double-stranded

contaminants,
primers.

including

PCR

amplified

primer-dimers

DNA

and

away

It
form

amplification

The DNA is eluted from the Magic PCR preps resin

(Promega Corporation, Madison, WI) in water free of salt or
Samples were then ready for

macromolecular contaminants.
direct sequencing.

Because the sequence is very GC rich and repetitive in
nature, sequence extension can be difficult.
problems

with

termination.
cycle

secondary

to

of

premature

determine

which

would

give

better

The first was the dsDNA Cycle Sequencing system

(Life Technologies,
fmol

causing

Thus, two methods were investigated for direct

sequencing

results.

structure

There are also

template

polymerase.

Inc.,
and

The

Gaithersburg,

an

second

MD)

end-labeled
was

the

which uses 50

primer

Fmol

with

kit

Taq

(Promega

Corporation, Madison, WI) which uses 500 fmol of template, an
end-labeled primer and Taq polymerase.

The kits were very

similar except for the 100-fold difference in the starting
template

(see Materials and Methods) .

The fmol

kit was

chosen to sequence a majority of the patient DNA because it
resulted

in

Optimization

clearer,

more

experiments

readable

were

done

sequence

further

increasing

the

in.

dsDNA

method starting template amount to see if that improved the
quality of the results, It did not.

Fmol allowed for clear

sequencing of the repeat region of patient DNA far enough in
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to narrow down the region where the deletion was located.
However, due to the repetitive nature of the DNA and lack of
restriction sites as landmarks, it made determining the exact
endpoints of the deletion impossible.
PCR sequencing reactions were carried out for either
method using the following

profile: 95°C for 3 minutes, 95°C

for

30

30

seconds,

62°C for

seconds,

72°C

for

1 minute,

repeating all but the first step for 19 cycles, then 95°C for
30 seconds, 70°C for 1 minute, for 9 more cycles.

Sequencing of the p4.6EP Subclone Repeat Region

Cycle

sequencing was

first

performed

on

the

p4. 6EP

subclone to verify that the region of interest was being
properly amplified, and to optimize methods (see Figure lOA) .
Both direct cycle sequencing methods were used, with the Fmol
method generating most

of

the

sequence.

obtained was an exact match to NT899

The

sequence

(see Figure 5) .

This

verified that the sequence that would be obtained from the
tandem repeat region of the patient DNA would be reliable.

Sequencing of the Repeat Region in Patient DNA

In order to sequence the patient DNA, the two fragments
must be separated to isolate only the band containing the
deleted allele.

This was done using bandstab PCR (Kadokami

et al., 1994; Bjourson et al., 1992).
amplified patient

DNA was

run

out

An aliquot of the PCR
on

a

high

percentage
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agarose

gel

(1. 5%) .

The

gel

was

stained with

ethidium

bromide, and viewed on a UV transilluminator (300nm) .

Excess

water was removed from the surf ace of the gel and the lower
band was stabbed from the gel with a hypodermic needle which
was then agitated into a normal PCR reaction mixture that was
prepared without any template.
same conditions as above.

PCR was carried out under the

An aliquot of the reaction was run

out on an agarose gel to verify amplification.
shows these results.
patient

genomic

Figure 9

Lane 2 is an aliquot of the original

amplification,

showing

approximately 790bp and 700bp in size.
shown in lanes 3 and 4.

the

two

bands

of

Bandstab results are

The top band is in lane three and

the bottom band (containing the deletion) is in lane 4.

This

shows the deletion to be approximately 90bp in size.
The bandstab PCR reaction for the deleted allele was
then

cleaned

extraneous

up

primer

in

order

by

(Promega Corporation,

the

to

remove

"wizard"

Madison,

WI) .

contaminants

PCR

clean-up

and

method

DNA cycle sequencing

reactions were then performed on this fragment and run on 8%
acrylamide sequencing gels.

Figure lOB is an example of the

patient sequence obtained by this method.

The region shown

is the same region as that in Figure lOA from the p4.6EP
subclone.

The sequences match exactly.

The PCR sequencing

reactions

accurately

patient

generating sequence of

amplified
the

the

template,

repeat/deletion region.

This

again verified that this was an effective, reliable method of
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determining the sequence of patient DNA.
The

deleted allele

for

this

patient

( 3C2)

was

then

sequenced to the extent possible as above and compared to the
entire NT899 sequence and the p4. 6 PCR product sequence.
sequence is shown in Figure 11.

The

Nucleotides sequenced are

shown aligned along the NT899 sequence for comparison.

The

available regions of patient sequence matched NT899 exactly.
No point mutations were present in the patient sequence.

The

region of the deletion is represented by the cross hatches.
The deletion region of approximately 125bp is shown in the
repeat aligned sequence of NT899 in Figure 12.
maximum size of the deletion region.

This is the

Since the sequence

could not be reliably read any further in from the primers.
The exact deletion endpoints could not be determined due to
the repetitive nature of the sequence and lack of restriction
sites to use as landmarks.

It was difficult to tell where

one repeat started and ended as you got further into the
deletion region.

PCR of the genomic patient DNA gave a

deletion size of approximately 90bp in length (see Figure 9) .
Thus the sequencing results and the PCR data indicate that
the deletion in this patient is approximately 90-125bp in
length.
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Figure 1. Restriction map of 4.6kb cloned fragment showing
the deletion location.
The new collagen-like locus on chromosome 17 was cloned from
a chromosome specific library as a 4.6kb HindIII restriction
fragment.
Restriction sites for the indicated enzymes are
shown.
Fragment sizes in base pairs are indicated.
The
location of Alu repetitive sequences are also indicated (*).
The locus contains a short triple helical coding region that
cross-hybridizes the the pro-a2(I) cDNA, Hf32 (bold line).
The region where ·deletions occur (as indicated by the bold
arrow) is located between the EcoRI and PvuII restriction
sites.
This is the same sequence where the 18bp tandem
repeats are located. The direction of transcription in this
locus is indicated by the horizontal arrow.
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Figure 2. Localization of deletion region.
A: Restriction digests of DNAs from a patient with a
homozygous 200bp deletion at Site 2 and from a normal
heterozygous individual were hybridized to the EcoRI/SstI
fragment of p4.6.
Lane
Lane
Lane
Lane
Lane
Lane
Lane
Lane
Lane
Lane

1,
2

patient
normal
patient
3
4,
normal
patient
5,
6,
normal
7,
patient
normal
8
patient
9,
10, normal
I
f

f

DNA
DNA
DNA
DNA
DNA
DNA
DNA
DNA
DNA
DNA

digest:
digest:
digest:
digest:
digest:
digest:
digest:
digest:
digest:
digest:

HindIII+BglI
Hind III+BglI
HindIII+EcoRI
HindIII+EcoRI
HindIII+PvuII
HindIII+PvuII
HindIII+PstI
HindIII+PstI
HindIII
HindIII

B: Restriction digests of DNAs from a patient with a
homozygous 200bp deletion at Site 2 and from a different
normal heterozygous individual were hybridized to the
EcoRI/SstI fragment of p4.6.
Lane
Lane
Lane
Lane

1,
2,
3,
4,

patient
normal
patient
normal

DNA
DNA
DNA
DNA

digest:
digest:
digest:
digest:

HindIII+EcoRI
HindIII+EcoRI
HindIII+PvuII
HindIII+PvuII

Comparing the fragments obtained in the patient to that
normal control allowed localization of the deletion
small region between PvuII and EcoRI sites.
This is seen as the loss of the second band in the
heterozygous individual, and both normal and patient
one band of the same size.

in the
to the
normal
having
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A.

1

2

3

4

5

6

7

8

9 10

-4,600
-3,900

-3,000

-2,300
-2,000
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B.
1

2

3

4

-3,000

-2,300
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Figure 3. Schematic diagram of the clones, subclones and PCR
products used to characterize the deletion site.
Only a
portion of the vectors are shown in the diagrams.
A: p4 . 6, the pUC13 vector containing the 4 . 6kb Hind I I I
fragment.
B: p4.6EP, the pUC13 vector containing the 1.6kb EcoRI/PstI
helical coding fragment.
C: p4.6ME, pGEM7Zf+ vector containing the 1.Skb EcoRI/SmaI
triple helical coding fragment.
D: Linearized p4.6ME and the resulting nested deletion
subclones generated by the "Erase-A-Base" system.
These
deleted subclones were recircularized prior to sequencing.
E: PCR product 4. 6EP, The PCR product generated using the
constructed pair of PCR primers that flank the tandem cluster
on the p4.6 EcoRI/PstI template.
F: PCR product Pt3C2, The PCR product generated using the
constructed pair of PCR primers that flank the tandem cluster
on a heteozygous patient genomic DNA template.
Sizes of fragments are indicated in base pairs.
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Figure 4. 8% acrylamide sequencing gel of Site 2 nested
deletions.
A typical example of the sequence generated using the "AmpliTaq" kit.
102 nucleotides can be read as pictured here
(position 643 to 745 of the NT899 sequence) . The PvuII site
sequence at position 680 is indicated. The letters at the top
indicate the nucleotide represented in the corresponding lane.
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GATCGTAC
-745

-Pvull

-643

57

1

EcoRI
GAATTCCAGT CACTCCCTCC AGGAGACACA CCAGCAGTGG TCAGGAAGCA

51

AGTCCACCAC AGCCTTCTGG AAAGGTCTCT AGTCTCAGGA GACACGAGCC

101

ACTCAAGCCT CCCACATGCC ACCAAAGAAG ATAAGCTGGC CCAGAGAAGA

151

CCAGCAGCCC AGAGAAGACC AGCAGCCTGG ACAAGACCAA CAGCCCAGAC
AvaII
Ava II
ATAGACCAGC AGCCCAGAAA GGACCAGCAG CCCAGACAGG ACCAGCAGCC

201
251
301
351
401

*

CAGGCAAGAC CAGCAGCCTG GACAAGACCA GCAGCCTGGA
AvaII
AGCCCAGACA TAGACCAGCA GCCCAGACAG GACCAACAGC
AvaII
ACCAGCAGCC CAGACAGGAC CAGCAGCCCA GACAAGACCA
PvuII
CAAGAACAGC TGGCCCAGCA GCCCATACAA GACCAGCAGC

CAAGACCAAC
CCAGACATAG
GCAGCCTGGA
CCAGATATAG

501

CCCAGCAGCC CAGACATAGC CCAGCAGCCC AGACAAGACC AGCAGCCCAG
PvuII
ACAAGACCAG CAGCCTGGAC AAGACCAGCA GCCAGGATAA GAACAGCTGG

551

CCCAGCAGCC CATACAAGAC CAGCAGCCCA GATATAGCCC AGCAGCCCAG

601
651

ACATAGCCCA GCAGCCCAGA CAAGACCAGC AGCCCAGACA AGACCAGCAG
PvuII
CCCGGACAAG ACCAGCAGCC AGGATAAGAA CAGCTGGCCC AGCAGCCCAT

701

ACAAGACCAG CAGCCCAGAC ATAGCCCAGC AGCCCAGACA AGACCAGCAG

751

CCCAGACAAG AACCAATCTG CCCAGGCTGC TCTTGGAGGG GGTTCTCTCA

801

GGATTCTCAG GCTCAAAGTA GGCCGAGCCT GGGTCATCAC CACTCCGGCA
AvaII
GCCCAAGTGG GACCTCCTGG GACAGGCTTC ATCTCCGCAC TTGCAGGAG

451

851

*

Figure 5. Complete nucleotide sequence of NT899.
Selected restriction sites
are
indicated above
their
recognition sequence.
Asterisks indicate the beginning and
end of the tandem repeat clusters. Numbers on the left margin
indicate the nucleotide position at the start of the line. A
space is inserted after every tenth nucleotide for easier
reading.
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Figure 6. Sequence of NT899 aligned to illustrate the 18bp
nucleotide direct repeats.
There are 34 repeats with a minimum of 83.4% identity to the
basic repeat and 3 brief insertions of 9 nucleotides each.
Single thymidine insertions also occur periodically.
The
carats indicate the exact location of the insertions which
have been removed and placed above the sequence they
interrupt.
The primers used to amplify the region are
indicated by the bold underline. Numbers to the left indicate
the re spec ti ve repeat. Numbers to the right indicate the
nucleotide position. Select restriction sites are indicated.
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GAATTeeAGTeAeTeeeTeeAGGAGACACAeeAGeAGTGGTCAGGAAGeA
AGTeCAeeACAGeeTTeTGGAAAGGTeTeTAGTeTeAGGAGACACGAGCC
ACTCAAGeeTeeeACATGeCAeCAAAG
127
T
1
A A G A T A A G evG G e e e A G A G
146
2

AAGAeeAGeAGeeeAGAG

3

A A G A e e A G e A G e e T G G A e

4

7

AAGAeeAAeAGeeeAGAe
T
AvA G A e e A G e A G e e e A G A A
AVAII
AGGAeeAGeAGeeeAGAe
AVAII
A G G A e e A G e A G e e e A G G e

8

AAGAeeAGeAGeeTGGAe

9

A A G A e e A G e A G e e T G G A e

10

14

A A G
T
AvA G
AVAII
A G G
T
AvA G
AVAII
A G G

15

A A G A e e A G e A G e e T G G A e

16

CAGCTGGee
A A G A Ave A G e A G e e e A T A e

5
6

11
12
13

50
100

182

219

255

291

A e e A A e A G e e e A G A e
A e e A G e A G e e e A G A e

328

A e e A A e A G e e e A G A e
A e e A G e A G e e e A G A e

365

A e e A G e A G e e e A G A e
401

PVUII

17

19

A A G A e e A G e A G e e e A G A T
T
AvA G e e e A G e A G e e e A G A e
T
AvA G e e e A G e A G e e e A G A e

20

A A G A e e A G e A G e e e A G A e

21

A A G A e e A G e A G e e T G G A e

22

A A G A e e A G e A G e e A G G A T

23

eAGCTGGee
A A G A Ave A G e A G e e e A T A e

18

446

484

520

PVUII

24

565

602

26

A A G A e e A G e A G e e e A G A T
T
AvA G e e e A G e A G e e e A G A e
T
AvA G e e e A G e A G e e e A G A e

27

A A G A e e A G e A G e e e A G A e

639

28

A A G A e e A G e A G e e e G G A e

29

A A G A e e A G e A G e e A G G A T

25

675

PVUII
30
31

CAGCTGGee
A A G A Ave A G e A G e e e A T A e
72 0

32

A A G A e e A G e A G e e e A G A e
T
AvA G e e e A G e A G e e e A G A e

33

A A G A e e A G e A G e e e A G A e

757

34

A A G A A e C A A T e T G e e e A G

GeTGCTCTTGGAGGGGGTTCTCTCAGGATTeTeAGGeTeAAAGTAGGe
eGAGeeTGGGTeATeAeeAeTeeGGeAGeeeAAGTGGGAeeTeeTGGG
AeAGGeTTeATeTeeGCAeTTGAeGGAG

823
871
899
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A.
PRIMER #1 FROM NT899 SEQUENCE
TO: NT899.seq;l
P4.6 M/E deletion subclone sequence
SCORES

Initl: 80 Initn: 80 Opt: 80
100.0% identity in 20 bp overlap
10

20

PRIMER
GGAGACACGAGCCACTCAAG
NT8 9 9
II II I II II I II I I I I I I I I
I I I I I I I I I I I I I I I I I I I I
CACAGCCTTCTGGAAAGGTCTCTAGTCTCAGGAGACACGAGCCACTCAAGCCTCCCACAT
60
70
80
90
100
110
GCCACCAAAGAAGATAAGCTGGCCCAGAGAAGACCAGCAGCCCAGAGAAGACCAGCAGCC
120
130
140
150
160
170

B.
PRIMER #2 FROM NT899 SEQUENCE
TO: NT899.seq;l
P4.6 M/E deletion subclone sequence
SCORES

Initl: 80 Initn: 80 Opt: 80
100.0% identity in 20 bp overlap
10

20

PRIMER
GCTCTTGGAGGGGGTTCTCT
NT899
I I I I I I I I I I I I I I I I I I I I
I I I I I I I I I I I I I I I I I I I I
AGCCCAGACAAGAACCAATCTGCCCAGGCTGCTCTTGGAGGGGGTTCTCTCAGGATTCTC
760
770
780
790
800
810
AGGCTCAAAGTAGGCCGAGCCTGGGTCATCACCACTCCGGCAGCCCAAGTGGGACCTCCT
820
830
840
850
860
870

Figure 7. Primer pattern analysis ~esults.
.
A: Fasta computer analysis of Primer 1 showing comp~ete
identity only with the region that exactly matches the primer
selected.
B: Fasta computer -~nalysis of Primer 2 showing complete
identity only with the region that exactly matches the primer
selected.
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1

2

3

4

5

6

23, 1309,4166,5574,361-

2,3222,0271,3531,078872-790
603-

310-

Figure 8. PCR amplification of repeat region.
Using primers synthesized from areas surrounding the tandem
repeats in Site 2, PCR amplification of the deletion regions
was possible.
Lane 1: molecular weight marker, Lane 2:
amplification of tandem repeat region in a unaffected
individual (BenVen), Lane 3: amplification of tandem repeat
region in Site 2 clone (p4.6EP), Lane 4, 5, 6: amplification
of tandem repeat region in three OI patients with · Site 2
deletions (Pt3C2, Pt20C2, Pt530).
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1

2

3

4

23,130- . . . .
9,4166,5574,3612,3222,0271,3511,078872-

-790
-700

603-

310-

Figure 9. Bandstab amplification of deleted region.
In order to sequence the deletion region in patient DNA, it
was necessary to determine which allele contained the
deletion.
Bandstab PCR was used to amplify each individual
allele and direct sequencing of the PCR-amplif ied fragment
from the deleted allele was performed.
Lane 1: molecular
weight marker, Lane 2: amplification of tandem repeat region
in OI patient, Lane 3: bandstab amplification of _ larger
patient allele, Lane 4: bandstab amplification of smaller
patient allele.

63
Figure 10. PCR direct sequencing acrylamide sequencing gels.
8% acrylamide sequencing gel of:
A: p4.6EP PCR product
B: bandstab amplification of deleted patient allele using the
"dsDNA cycle sequencing system". The AvaII sites at positions
220 and 237 respectively are indicated.116 nucleotides can be
read as pictured here (position 160 to 276 of the NT899
sequence) .
The letters at the top indicate the nucleotide
represented in the corresponding lane.
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A.

B.
GATCGTAC
276-

Avall-

Avall-

160160-
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EcoRI

1

---------- ---------- ---------- ---------- ----------

51

---------- ---------- ---------- -------GGA GACACGAGCC

101

ACTCAAG--- CCCACATGCC ACCAAAGAAG ATAAGCTGGC CCAGAGAAGA

151

CCAGCAGCCC AGAGAAGACC AGCAGCCTGG ACAAGACCAA CAGCCCAGAC

201

ATAGACCAGC AGCCCAGAAA GGACCAGCAG CCCAGACAGG ACCAGCAGCC

251

CAGGCAAGAC CAGCAGCCTG GACAAGACCA GCAGCCTGGA CAAGACCAAC

301

AGCCCAGACA TAGACCAGCA G///////// ////////// //////////

351

////////// ////////// ///Ill//// ////////// //////Ill/

401

////////// ////////// ////////// ////////// //////ATAG

451

CCCAGCAGCC CAGACATAGC CCAGCAGCCC AGACAAGACC AGCAGCCCAG

501

ACAAGACCAG CAGCCTGGAC AAGACCAGCA GCCAGGATAA GAACAGCTGG

551

CCCAGCAGCC CATACAAGAC CAGCAGCCCA GATATAGCCC AGCAGCCCAG

601

ACATAGCCCA GCAGCCCAGA CAAGACCAGC AGCCCAGACA AGACCAGCAG

651

CCCGGACAAG ACCAGCAGCC AGGATAAGAA CAGCTGGCCC AGCAGCCCAT

701

ACAAGACCAG CAGCCCAGAC ATAGCCCAGC AGCCCAGACA AGACCAGCAG

751

CCCAGAC--- ---------- --------GC TCTTGGAGGG GGTTCTCT--

801

---------- ---------- ---------- ---------- ----------

851

---------- ---------- ---------- ---------- ---------

*

Ava II

Ava II

Ava II
Ava II
PvuII

PvuII

PvuII

*

Ava II

Figure 11.
Schematic diagram of 4. 6kb clone sequence and
patient DNA sequence aligned.
Restriction sites are indicated above their recognition
sequence as they were in NT899. Portions represented by lines
were not sequenced in the patient. The region represented by
the bold cross hatches indicates the region where the deletion
is located.
Actual endpoints are estimated.
Asterisks
indicate the beginning and the end of the tandem repeat
clusters. Bold, underlined nucleotides indicate the primers
used to amplify the repeat region and cycle sequence. Numbers
on the left margin indicate the nucleotide position at the
start of the line.
A space is inserted after every tenth
nucleotide for easier reading.
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Figure 12. Schematic diagram of direct repeats in NT899
indicating deletion region.
Cross hatches indicate the deletion region. Bold, underlined
nucleotides indicate the primers used for amplification and
sequencing.
Numbers to the left indicate the respective
repeat.
Numbers to the right indicate the nucleotide
position. Select restriction sites are indicated.
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GAATTCCAGTCACTCCCTCCAGGAGACACACCAGCAGTGGTCAGGAAGCA
AGTCCACCACAGCCTTCTGGAAAGGTCTCTAGTCTCAGGAGACACGAGCC
ACTCAAGCCTCCCACATGCCACCAAAG 127

50
100

T

1

A A G A T A A G CvG G C C C A G A G

14 6

2

A A G A C C A G C A G C C C A G A G

3

A A G A C C A G C A G C C T G G A C

4

AAGACCAACAGCCCAGAC

5

7

AvA G A C C A G C A G C C C A G A A
AVAII
AGGACCAGCAGCCCAGAC
AVAII
A G G A C C A G C A G C C C A G G C

8

AAGACCAGCAGCCTGGAC

9

A A G A C C A G C A G C C T G G A C

10

A A G A C C A A C A G C C C A G A C

11

AvA G A C C A G C A G I I I / / / I 328
AVAII

12

I I I I I I I I I I I I I I I I I I
I
/v/ I I I I I I I I I I I I I I I I

182

T

6

219

255

291

T

13

365

AVAII
14

I I I I I I I I I I I I I I I I I I

15

I I I I I I I I I I I I I I I I I I

4 01

PVUII
/////////

16

I I I I /v I I I I I I I I I I I I I

11

I I I I I I I I I I I I I I I I I I

446

T

18

AvA G C C C A G C A G C C C A G A C

19

AvA G C C C A G C A G C C C A G A C

20

A A G A C C A G C A G C C C A G A C

21

A A G A C C A G C A G C C T G G A C

520

22
23

A A G A C C A G C A G C C A G G A T
PVUII
CAGCTGGCC
A A G A AvC A G C A G C C C A T A C

565

24

A A G A C C A G C A G C C C A G A T

25

AvA G C C C A G C A G C C C A G A C

T

484

T

602

T

26

AvA G C C C A G C A G C C C A G A C

27

A A G A C C A G C A G C C C A G A C

28

A A G A C C A G C A G C C C G G A C

29

675

30

A A G A C C A G C A G C C A G G A T
PVUII
CAGCTGGCC
A A G A Ave A G c A G c c c A T A c

31

A A G A C C A G C A G C C C A G A C

720

639

T

32

AvA G C C C A G C A G C C C A G A C

33

A A G A C C A G C A G C C C A G A C

34

A A G A A C C A A T C T G C C C A G

757

GCTGCTCTTGGAGGGGGTTCTCTCAGGATTCTCAGGCTCAAAGTAGGC
CGAGCCTGGGTCATCACCACTCCGGCAGCCCAAGTGGGACCTCCTGGG
ACAGGCTTCATCTCCGCACTTGACGGAG

823
871
899

CHAPTER V
DISCUSSION

This work involves characterization of the deletions in
a newly discovered human collagen-like locus associated with
osteogenesis

imperfecta.

Spontaneous

deletions

of

heterogeneous size occur at the Site 2 locus more frequently
in OI Type III patients than in normal individuals (Doering
et

al.,

1987).

This

suggests

that

the

defect

in

the

structure of the protein coded for by Site 2 can contribute
to the OI phenotype.

The goal of this study was to locate

the deletion site in the 4.6kb Hind III Site 2 fragment, and
analyze the molecular structure of this region in affected
individuals.

This allowed the deletion to be more precisely

localized

and

occurrence

of

suggested
deletions

a
at

mechanism
this

site.

developed here will also be useful

for
The

the

frequent

PCR methods

in eventual

screening

programs for identifying individuals carrying deletions at
Site 2.

Region of Deletion
Initially the deletion in the Site 2 locus was localized
by Southern blotting to the region between the EcoRI and
68
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PvuI I

sites in one patient

(see Figure 1) .

collagen-like helical coding region.

This is the

The full sequence of

this region revealed 34 direct repeats composed of an 18bp
consensus

repeating

unit

(see

Figure

7) .

To

determine

whether this repeat region is the major site for deletions,
primers were synthesized that flanked the region, and PCR was
performed on a normal individual, and multiple OI Type III
patients.

Four out of five patients amplified were either

heterozygous or homozygous for a deletion in this region.
The deletions were of heterogeneous size from patient to
patient ranging from 60-340bp in length.

The one patient

that only had one normal-sized fragment by PCR could have a
Site 2 deletion that extends outside the tandem repeats.
Deletions are often found that extend from tandemly repeated
sequences
Zuliani

et

into
al.,

adjacent

regions

1990).

In any

(Willing
case,

et

these

al.,

1988;

PCR results

demonstrate that Site 2 deletions are primarily localized to
the cluster of 18bp repeats.

Direct sequence data obtained

from one patient indicates that the deletion is actually in
the tandem repeat cluster and not in immediately adjacent
sequences (see Figure 11 and 12).

The patient sequence also

contained no point mutations.

Repetitive Nature of the Sequence
Repetitive sequences with relatively short basic repeat
units

(2-25 nucleotides)

are known to be responsible for
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deletions which lead to length polymorphisms (Stoker et al.,
1985; Lee et al., 1991; Sykes et al., 1990).

For example,

collagen-like sequences on chromosome 11 have substantial
length polymorphisms from variable numbers of a tandem repeat
(Brooks

et

al.,

1989) .

There

are

reports

of

a

region

adjacent to the COL2Al gene which exhibits a high degree of
length polymorphism due to the variation in the number of
copies of a simple tandemly repeating dinucleotide sequence
(Sykes et al., 1985; Stoker et al., 1985).

The COL3Al gene

contains a polymorphic block of dinucleotide repeats in one
intron (Lee et al., 1991).

Direct repeats have been shown to

cause deletions in the helical coding portions of the COLlAl
and COL1A2 collagen genes leading to the OI phenotype (Chu et
al., 1985; Hawkins et al., 1991; Willing et al., 1988).

A

38bp insertion/deletion is a common polymorphism within an
intron

of

the

COL1A2

gene

(Dalgleish

et

al.,

1986).

Recombination between direct Alu sequence repeats can cause
clinical pathologies due to deletion of coding information
(Stoppa-Lyonnet et al., 1990).
The organization of the 18bp tandem repeat of NT899 is
much

like

that

of

the

direct

repeats

which

cause

polymorphisms seen in other collagen and non-collagen genes
(Richards

et

al.,

1992;

Zuliani

et

al.,

1990).

Each

repeating unit, AAG ACC AGC AGC CCA GAC, has an average of
93. 3%

identity

to

this

sequence.

Since

there

is

high

identity between the repeats of NT899, and they extend over
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at least 617 base pairs, misalignment during DNA replication
not only seems possible, but highly probable.

Also,

since

most of the deletions seen in the OI patients are in the
tandem

repeat

repetitive

cluster,

organization

it

strongly

facilitates

suggests
the

that

deletions.

this
The

absence of point mutations in the patient sequence eliminates
them as the cause of the deletions.
that

the direct

It is therefore likely

repeat organization is

the

cause of

the

length variations seen at the Site 2 locus.

Deletion Mechanism
Direct

repeats

are

frequently

involved

in

causing

deletions, including within collagen genes (Chu et al., 1985;
Hawkins et al., 1991; Richards et al., 1992).

The probable

mechanism involved is slipped mispairing (Richards et al.,
1992), where during replication one direct repeat misaligns
with another on the complementary strand causing looping out
and subsequent excision of the intervening DNA (Ef stradiadis
et al.,

1980).

Also,

homologous chromosomes may misalign

within the tandem cluster during meiosis, causing some of the
DNA to loop out, creating deletions and frameshift mutations.
Such repeat-mediated deletions appear to be occurring at
Site 2.
al,

Since the deletions occur spontaneously (Doering et

1987)

the slipped mispairing must be occurring during

meiosis in the parent of an OI child or during early cell
divisions in the embryo that will develop OI.

The number of
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tandem repeats may be a factor in the occurrence of slipped
mispairing

and deletions.

Large clusters would facilitate

more frequent slipped alignments.

The number of tandem 18bp

clusters found in NT899 is apparently large enough to make
the region deletion prone.

These tandem repeat clusters are

thus unstable and can change each time they are transmitted
from parent to child (Sutherland and Richards, 1994) .

Also,

deletions are often found that extend from tandemly repeated
sequences

into

adjacent

Willing et al.,

1988) .

regions
Thus,

(Zuliani

et

al.,

in some cases,

patient described in the present study,

as

in one

Site 2 deletions

could be extending outside the 18bp tandem repeats.
mispairing

1990;

Slipped-

would not be the cause of this deletion.

The

specific location or extent of deletion within Site 2 may
play a role in the expression of the OI phenotype.

It is

possible that individuals heterozygous for small deletions
may be less affected,

if at all,

than individuals who are

either heterozygous for larger deletions or homozygous for
deletions at this locus.

Relation to Other Repeat Disorders
Fascioscapulo-humeral muscular dystrophy

(FSHD)

is

associated with deletions in a tandemly repeated sequence
(Winokur

et

al.,

1994) .

The

cluster of

3. 2kb

tandemly

repeated unit is located on chromosome 4 and deletions in
this

region

of

at

least

6kb

show

tight

linkage

to

the
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disease.

The repeat cluster is actually adjacent to the FSHD

gene, and how the deletions affect its expression is not yet
known.

Slipped-strand mispairing can also result in the

duplication or amplification of repeated sequences.
repeat

clusters

which

expand

in

size

are

Triplet
sites

the

of

mutation in three heritable disorders, myotonic dystrophy,
fragile X syndrome, and spinal and bulbar muscular atrophy.
In these disorders,

premutation or precursors of the full

mutation alleles contain triplet-repeat sequences which, when
amplified

beyond

a

crucial

threshold

number,

result

in

mutated alleles that cause the expression of the disease
(Caskey et al., 1992).

Parents with

repeat cluster sizes

below a specific threshold have mild or no disease, but give
rise to significantly amplified repeats in progeny, who have
the

full

disease

phenotype

(Caskey

et

al.,

1992).

The

sequence amplifications that result in the disease phenotype
in

these

patients

is

analogous

associated with Type III OI.

to

the

Site

2

deletions

The parental deletions we have

observed in OI families may be analogous to the premutation
alleles.

They could then give rise to the OI phenotype in

offspring by further slipped-mispairing deletions.

Further

work will investigate if such premutation alleles exist in OI
patients.

74

An Expressed Collagen-Like Gene
There

is

strong

genetic

evidence

that

Site

2

is

expressed, and that some of its deleted genotypes can lead to
a

detrimental

phenotype

Doering et al., 1993).

against

which

selection operates

The association of Site 2 deletions

with OI Type III is one example of such a phenotype.
Computerized analysis of the Site 2 sequence shows the
presence

of

long

open

reading

frames

in

the

translation frames (left to right in Figure 1) .
potential

reading

frames,

codon preference,

reverse

Analysis of
and

GC bias

suggests that the reverse translation frames contain coding
information that could occur in a gene that is expressed
(Cammarata, 1994) .

The data are consistent with the presence

of an expressed, collagen-like sequence being present on the
reverse strand.
Dot blot hybridizations of total RNA from normal diploid
human fibroblasts to p4.6 sequences confirms that Site 2 is
transcribed

(Breslin

et

al.,

1995) .

Transcription

experiments indicate that the gene is transcribed in the left
to right direction on the restriction map as seen in Figure
1

(Breslin et al., 1995).

This is consistent with all the

computer data that the Site 2 locus is an expressed collagenlike gene.
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Possible Function of the Site 2 Locus
The

level

of

GC

richness

(63%)

seen

in

the

NT899

sequence is similar to that of other collagen and connective
tissue (ECM) genes (Bernard et al., 1983) .Previous sequence
comparisons of NT899 (Cammarata, 1994), have identified high
similarity to a number of ECM components and transmembrane
glycoproteins,

which

are

important

in

directing

the

composition and structure of the extracellular matrix and
effecting cellular interactions with the matrix (Alberts et
al., 1994).

This supports a function in which the putative

protein encoded by

the

interaction of Type

I

acting as

a

Site

2

locus

could modulate

collagen fibrils

with the

communication bridge between them

Olsen,

1991).

which

directs

the

cell by

(Shaw and

This is possible via a signaling function
the

secretion

structural capacity,

of

ECM

components

or

in

a

somehow connecting or associating the

major fibril with other cell-secreted ECM components (MullerGlauser et al., 1986).
The

sequence

interrupted

pattern

collagen

in

triplet

the

Site

sequence

2

which

gene

is

contains

an
a

substitution for a glycine rather than a missing glycine.
This pattern suggests that this molecule has the potential
for flexibility while still maintaining a collagen-like ahelical structure (Sandell et al., 1990).

Cysteine residues

allow inter- and intra-molecular crosslinking of the collagen
polypeptide and are important in determining the structure of
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the

terminal

globular domains

(Ninomiya et al., 1990).
p4. 6 suggest
farming

other

that

of

the

Type

molecules

The abundance of these residues in

the gene product has

higher

IX

order

structures

the
in

capacity for

addition

to

a

typical a-helix.
Abnormal Type I collagen incorporated into fibrils has
a drastic effect on tissue integrity,
phenotype (Prokop et al., 1989).

resulting in the OI

Since the Site 2 collagen-

like gene is associated with the OI phenotype

(Doering et

al., 1987), it is likely that defects in its protein product,
which result from deletion, will also contribute to the OI
phenotype.

Because the exact structure of the protein has

not yet been identified, it is difficult to say specifically
how these deletions affect its structure.
If the Site 2 gene product does modulate Type I fibril
interactions,

then

strength

structural

and

containing tissue.

it

has

the

potential

integrity

of

to

Type

affect
I

the

collagen

Thus, defects in p4.6 that disrupt this

interactive capacity, could in turn effect the expression of
the OI phenotype where a Type I collagen defect is or is not
present.

For example,

there are many cases described where

substitutions for glycine in similar positions of the same
Type I collagen chain can produce drastic differences in OI
severity between individuals (Cohn et al., 1991; Rose et al.,
1995;

Forline

et

al.,

1994) .

It

is

possible

that

the

additional presence of a Site 2 mutation could cause the more
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severe condition, such as that seen in Type III OI.

In some

cases a single defect at the Site 2 locus could in itself
result in the Type III OI phenotype.
The deleted allele at Site 2 may not cause OI directly,
but rather the defective product of the locus may interact
with other mutant connective tissue components (such as Type
I collagen)

in producing the OI phenotype.

There are many

examples of asymptomatic individuals carrying the same Type
I collagen defect as their family members that have OI (Cohn
and Byers, 1991; Constantinou et al., 1989; Hollister et al.,
1988) .

This suggests that the disease phenotype requires an

interaction between Type I collagen and the products of other
Site 2 is a very good candidate for such a locus.

loci.

Future work will determine if the size or location of Site 2
deletions can be correlated with severity of symptoms in
patients.

Importance as a Diagnostic Tool
Site 2 does not code for a true collagen molecule, but
rather a protein with short collagen-like domains (Thiel and
Reid,

1989).

Whatever its product,

the newly discovered

locus is of importance, since our studies on OI patients and
their families demonstrate that deletions at these sites are
clearly

associated

with

the

disease

and

might

serve

as

reliable diagnostic/genetic counseling markers for Type III
OI.

PCR screening of the repeat/deletion region could be a
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simple,

effective diagnostic indicator.

This could be of

real value for the many Type III cases not associated with
Type

I

collagen

defects,

and

could

help

in

predicting

severity of cases that do contain Type I defects.
The PCR primers that flank the tandem repeat region in
Site

2

amplify

a

71lbp

sequence,

which

is

a

much more

sensitive means for detecting deletions than the Southern
blot protocol (Doering et al., 1993), which used the entire
4. 6kb Site 2 fragment.

Being able to isolate the repeat

region in a small fragment should detect short deletions and
heterogeneity that previously went undetected.

Deletions at

the site would result in shorter than normal fragments being
generated by the PCR.
DNA

fragments

Simple comparison of the sizes of the

generated

from

each

sample

would

permit

identification of individuals with a deletion, and what size
the deletion is.

Any sample that shows a Site 2 deletion by

Southern blotting but does not show a deletion by PCR, would
indicate that the deletion occurs outside the tandem repeat
region.

Future Studies
We

have

already

demonstrated

the

use

of

cycle

sequencing to directly sequence PCR-amplified fragments in
the Site 2 deletion region.

It will also be important to

examine the detailed sequences of deletions in some patients
and their asymptomatic parents.

Comparing the detailed
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structures of the deletions in a patient and the asymptomatic
parent could further elucidate the deletion mechanism and
indicate whether the parent's deletion is an intermediate in
the process of converting a normal allele to the patient's
allele.

Any

correlation between

the

deletion

size

and

severity of symptoms could eventually be a useful diagnostic
tool.

Also deletions in the normal population should be

studied to see how their deletion sizes compare to those in
patients and their parents.

Comparing the normal deletions

to those in asymptomatic parents would show if there is a
premutation not found in the normal population, which could
serve as a marker to identify individuals predisposed to
having a child with the OI phenotype.
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CHARACTERIZATION OF DELETION SITES
IN A HUMAN COLLAGEN-LIKE LOCUS

Osteogenesis imperfecta (OI) is a highly heterogeneous
genetic

disorder

that

affects

tissues rich in Type I collagen.

bone

and

other

connective

Previous studies have shown

the existence of two previously-undescribed collagen-like
loci,

with sequence similarity to pro-a2(I)

collagen.

At

these two sites deletions of heterogeneous size are found to
be significantly more prevalent in OI type III patients than
in the unaffected population.
This study determined the molecular organization of the
deletion site in one of the new collagen-like loci (Site 2).
Sequencing reveals that the locus contains a region with 34
copies of an 18bp tandemly-repetitive sequence.

Using blots

of restriction digested DNA from unaffected and OI patients,
and PCR primers that flank the cluster of tandem repeats, I
demonstrated that the deletions observed at this locus in OI
patients

usually

occur

within

the

tandem

molecular nature of the deletions was

cluster.

The

then determined by

comparing the sequences of a short allele in an OI patient to
the

normal

allele.

The probable mechanism creating the

deletions is slipped mispairing of misaligned repeats during
DNA replication.

